Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis
- 29 August 2006
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Emerging Drugs
- Vol. 11 (3) , 379-401
Abstract
More than 70% of patients with Type 2 diabetes mellitus (T2DM) die because of cardiovascular diseases. Current therapeutic strategies are based on separate treatment of insulin resistance and dyslipidaemia. Development of drugs with multimodal activities should improve management of the global cardiovascular risk of T2DM patients and result in better patient compliance. New therapeutic strategies are aimed at targeting the entire spectrum of dysfunctioning organs, cells and regulatory pathways implicated in the pathogenesis of T2DM, dyslipidaemia and atherosclerosis. PPAR family members play major roles in the regulation of lipid metabolism, glucose homeostasis and inflammatory processes, making these transcription factors ideal targets for therapeutic strategies against these diseases. This review discusses why PPARs and development of novel selective PPAR modulators, dual and pan PPAR agonists constitute promising approaches for the treatment of diabetes, dyslipidaemia and atherosclerosis.Keywords
This publication has 181 references indexed in Scilit:
- Indol-1-yl Acetic Acids as Peroxisome Proliferator-Activated Receptor Agonists: Design, Synthesis, Structural Biology, and Molecular Docking StudiesJournal of Medicinal Chemistry, 2006
- Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillationMedical Hypotheses, 2006
- Novel time-dependent vascular actions of Δ9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gammaBiochemical and Biophysical Research Communications, 2005
- Thiazolidinediones inhibit TNFα induction of PAI-1 independent of PPARγ activationBiochemical and Biophysical Research Communications, 2005
- A New Class of Peroxisome Proliferator-activated Receptor Agonists with a Novel Binding Epitope Shows Antidiabetic EffectsJournal of Biological Chemistry, 2004
- MK-0767, a novel dual PPARα/γ agonist, displays robust antihyperglycemic and hypolipidemic activitiesBiochemical and Biophysical Research Communications, 2004
- Resistin is expressed in human macrophages and directly regulated by PPARγ activatorsBiochemical and Biophysical Research Communications, 2003
- Cloning and Characterization of a Functional Peroxisome Proliferator Activator Receptor-γ-responsive Element in the Promoter of the CAP GeneJournal of Biological Chemistry, 2000
- Activation of PPARα or γ Reduces Secretion of Matrix Metalloproteinase 9 but Not Interleukin 8 from Human Monocytic THP-1 CellsBiochemical and Biophysical Research Communications, 2000
- Increased sensitivity of fat cell adenylate cyclase to stimulatory agonists during fasting is not related to impaired inhibitory coupling systemFEBS Letters, 1986